


[12] Patent

[11] Patent No.: GC 0000105	Number of the Decision to Grant the Patent: 5/210
[45] Date of Publishing the Grant of the Patent: 29/06/2005 4/2005	Date of the Decision to Grant the Patent: 15/03/2005
[21] Application No.: GCC/P/1999/203 [22] Filing Date: 14/07/1999 [30] Priority: [31] Priority No. [32] Priority date [33] State 9815567.4 1998/07/18 GB [72] Inventors: 1- Ian Gordon Armitage, 2- Hardev Singh, 3- Andrew David Searle [73] Owner: Glaxo Group Limited, Glaxo Wellcom House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England [74] Agent: Suleiman Ibrahim Al-Ammar	[51] Int. Cl. <sup>7</sup> : C07F 9/655; A61K 31/655 // C07D 307/20; C07C 311/18 [56] Cited Documents: - WO 9405639 A1 (VERTEX PHARMACEUTICALS CORPORATION) 17 March 1994

[54] CALCIUM (3S) TETRAHYDRO-3-FURANYL (1S, 2R)-3-[[4-AMINOPHENYL) SULFONYL](ISOBUTYL) AMINO]-1-BENZYL-2- (PHOSPHONOOXY) PROPYLCARBAMATE

[57] Abstract: The invention relates to calcium (3S) tetrahydro-3-furanyl (1S, 2R)-3-[[4(aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2- (phosphonooxy) propylcarbamate, to processes for its preparation, and to its use in the treatment of diseases caused by retroviruses.



No. of claims: 19

No. of figures: 1

